French biotech Abivax is up 2.11% at €99.15 in early afternoon trading, in a Paris market trending upwards. The SBF 120 is up 0.55% during the session. The stock maintains an exceptional annual performance, up over 1700%, despite a nearly 10% decline over the last three months.
A Stock Stuck Below its 20 and 50-Day Moving Averages After Quarterly Decline
The share price is below the 20-day moving average at €100.52 (a gap of -1.36%) and below the 50-day moving average at €100.81. These two close benchmarks form a short resistance zone that caps today's rebound. However, the 200-day moving average at €91.92 remains well below the current price, about 7.87% lower, indicating that the fundamental annual trend is still bullish despite recent consolidation. The RSI at 45 is neutral, showing neither overselling nor a marked increase in buying interest. The technical support identified at €93.50 was preserved during the decline, and the next resistance is at €110.20, a level approached in early May following a $45 million ADS raise and the buyback of royalty certificates.
Net Short Positions Slightly Decrease, at 2.49% of Capital
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to reviewed statements, three funds hold a combined net short position representing 2.49% of the capital, with the latest declaration dated May 14, 2026. Over thirty days, this total has decreased by 0.32 points (from 2.81% a month earlier). This movement does not indicate a capitulation by short sellers, but it does suggest that some have reduced their bearish exposure on the stock. The level remains to be monitored without being overinterpreted in isolation. The next technical threshold to watch remains the €100.52 - €100.81 zone, where the two short moving averages converge.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
